23andMe’s Therapeutics division focuses on research and drug development.
The team is committed to discovering and developing novel therapies to improve patient lives through the study of human genetics. We currently have research programs across several therapeutic areas, including but not limited to oncology, respiratory, and cardiovascular diseases.
In July 2018, 23andMe and GlaxoSmithKline (GSK) signed an exclusive agreement to leverage genetic insights for the development of novel medicines. This multi-year collaboration is expected to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programs.
